u/wisdom_man1

Interfyl is a placental connective tissue matrix that may support soft tissue remodeling in select tendon, ligament, fascia, and other connective tissue conditions.

https://www.espmedicine.com/services/interfyl-r-human-connective-tissue-matrix

Article summary

Mesenchymal stem cells (MSCs) are increasingly recognized for their potential in regenerative medicine, particularly in skin repair and rejuvenation due to their unique properties such as multipotency and immunomodulatory effects. This review highlights advancements in MSC-based therapies, emphasizing the benefits of neonatal and placenta-derived MSCs, and discusses various delivery strategies that enhance their therapeutic efficacy in treating skin conditions and promoting aesthetic improvements.

https://link.springer.com/article/10.1007/s44368-026-00031-0

​

One of the most important lessons aging biology has taught us is that nothing ages in isolation.

Muscle health influences metabolism.

The immune system shapes tissue repair.

Chronic inflammation affects cognition, cardiovascular health, and metabolic function.

Every major hallmark of aging is connected to another.

That realization changes how we should think about therapeutic development.

For decades, drug discovery has largely focused on identifying the right target.

Longevity challenges us to think differently.

Perhaps the goal is not simply to modulate a single pathway but to restore function across interconnected biological systems.

This is one reason cell-based therapies continue to attract scientific interest.

Rather than acting through a single mechanism, cells communicate through dynamic networks of cytokines, growth factors, extracellular vesicles, and direct cell-to-cell interactions. Their effects are context-dependent and continue to be actively investigated across a range of therapeutic applications.

Whether this system-level biology ultimately translates into meaningful clinical benefit remains an important scientific question.

But I believe the strategic direction is becoming increasingly clear:

As aging is increasingly understood as a system-level process, therapies capable of influencing multiple interconnected biological pathways may become an important part of the future therapeutic landscape.

The future of longevity medicine may not be about finding one master switch.

It may be about restoring the communication between biological systems that aging gradually disrupts.

If aging is fundamentally a systems problem, should we continue developing therapies one pathway at a time?

 

Item 1.01. Entry into a Material Definitive Agreement.

 

On June 29, 2026, Celularity Inc. (the "Company”) entered into a Loan Agreement (the "Loan Agreement”) with the Philip & Daniele Barach Family Trust (the "Lender”), a trust affiliated with Philip Barach, who is known by the Company to beneficially own more than five percent of the Company’s outstanding Class A common stock. Pursuant to the Loan Agreement, the Lender agreed to make a secured loan to the Company in the principal amount of $1,000,000.

 

The loan bears interest at 4.0% per annum, increasing to 18.0% per annum upon an event of default at the Lender’s election, and matures on the earlier of (i) 30 days after closing and (ii) the Company’s receipt of gross proceeds from certain financing or other strategic transactions. The loan is secured by a first-priority security interest in substantially all of the Company’s personal property, subject to customary excluded assets and permitted liens, including equipment and other assets subject to the existing security interest in favor of Helena Global Investment Opportunities 1 Ltd. The Loan Agreement also contains customary representations and warranties, covenants and events of default. As a condition to funding, Robert J. Hariri, M.D. entered into a waiver and subordination agreement with respect to indebtedness owed to him by the Company.

Abstract:

Reconstruction of oral soft-tissue defects remains limited by donor-site morbidity and inconsistent healing with currently available grafts. In this prospective interventional study, we assessed human amniotic membrane (HAM) as a biologically active scaffold in 15 patients (6 cleft alveolus, 2 oral submucous fibrosis, 7 vestibuloplasty; ages 8–65 years). HAM integrated without complications in all

cases, with no necrosis, infection, or immunologic rejection; median pain (VAS) fell from 2 on day 1 to 0 by day 7 (p < 0.00001) and swelling resolved by day 7 (p < 0.00001). Epithelialization reached "good" by 1 month (p < 0.00001); mucosal suppleness remained preserved through 6 months and in OSMF cases interincisal opening improved to 35–50 mm. Thus, data shows the HAM as a safe, donor-site–sparing, clinically translatable biomaterial that accelerates healing and improves function in oral soft-tissue reconstruction.

Conclusion:

Amniotic membrane exhibited substantial regenerative

potential, functioning as a biologically active scaffold that

enhanced epithelialization, preserved mucosal pliability,

minimized post-operative morbidity and prevented graft

exposure. Data support its emerging role as a versatile

biomaterial for oral soft tissue reconstruction. These present study provide a foundation for future controlled clinical studies.

Advancement to knowledge:

The present study shows that hAM use leads to reduced early post-operative pain and swelling, faster epithelialization within one month and sustained mucosal suppleness on follow-up. It evaluates three challenging conditions vestibuloplasty, OSMF and cleft alveolar defects expanding evidence beyond isolated defect reports. Findings support hAM as a readily available biological dressing that avoids donor-site morbidity and promotes favorable wound healing, with consistent graft adherence and no infection. Overall, the study provides comparative clinical evidence across multiple oral reconstructive procedures and reinforces the translational value of hAM in maxillofacial regeneration.

https://www.bioinformation.net/022/973206300223527.pdf

&amp;#x200B;

Biocellgraft is aiming to revolutionize regenerative dentistry with OraFyl,  offering an unprecedented level of usability. Derived from the chorionic part of the human placenta, a highly purified native collagen and elastin combination create a product of unparalleled effectiveness without additional adjuvants or cross-linkers.

Three Product Forms Offer Unprecedented Usability and the unique composition allows versatile and straightforward clinical applications.

1. The Flowable Gel Form simplifies direct injections into soft tissues, significantly enhancing ease of use in various clinical scenarios.

It's Minimally Invasive Application reduces patient morbidity and expands clinical possibilities by eliminating the need for invasive harvesting of patient tissues. This facilitates a smoother, faster, and less painful recovery process.

Convenient Handling and a long shelf life of up to 10 years in dehydrated form at room temperature, OraFyl is readily available and easily reconstituted with saline in a straightforward 50/50 ratio, making it highly convenient for clinicians.

2. The Injectable Form allows for soft tissue management around implants, restorations, and augmentation of keratinized tissue.

\-Specifically gingival biotype issues and gingival recession.

\-Correction of interdental papilla loss (“black triangles”).

\-And Enhancements such as lip augmentation and repair of orthodontic-induced gingival invaginations.

3. The Mixable Form Is Designed For:

\-Activation of bone grafting materials for ridge augmentation.

\-Treatment of bone defects at tooth or implant sites.

\-Management of challenging conditions like osteonecrosis and cleft-palate surgery.

Exceptional Healing Outcomes in Clinical studies demonstrate OraFyl’s significant advantages:

\-Accelerated Tissue Integration and Healing: Its molecular scaffold supports the recruitment and colonization of essential cells such as fibroblasts, osteoblasts, and macrophages, facilitating rapid healing.

\-Predictable Clinical Outcomes: OraFyl reliably achieves desired soft and hard tissue volumes and shapes, crucial for effective long-term management and patient satisfaction.

\-Reduced Soft Tissue and Bone Resorption: Clinical data shows OraFyl significantly reduces tissue shrinkage and bone resorption compared to traditional methods, highlighting its superior performance in alveolar ridge preservation.

Immunological Safety and Compatibility

A remarkable aspect of OraFyl’s usability is its immunological purity, ensuring biocompatibility and minimizing immune reactions. The absence of exogenous growth factors further contributes to a safe healing environment guided by the body’s natural regenerative capabilities.

Final Thoughts

OraFyl’s record-level usability not only simplifies clinical procedures but also enhances patient comfort and outcomes. Its versatility, combined with ease of application and exceptional healing properties, positions OraFyl as the next game-changing advancement in regenerative dentistry.

&#x200B;

Biocellgraft is aiming to revolutionize regenerative dentistry with OraFyl,  offering an unprecedented level of usability. Derived from the chorionic part of the human placenta, a highly purified native collagen and elastin combination create a product of unparalleled effectiveness without additional adjuvants or cross-linkers.

Three Product Forms Offer Unprecedented Usability and the unique composition allows versatile and straightforward clinical applications.

1. The Flowable Gel Form simplifies direct injections into soft tissues, significantly enhancing ease of use in various clinical scenarios.

It's Minimally Invasive Application reduces patient morbidity and expands clinical possibilities by eliminating the need for invasive harvesting of patient tissues. This facilitates a smoother, faster, and less painful recovery process.

Convenient Handling and a long shelf life of up to 10 years in dehydrated form at room temperature, OraFyl is readily available and easily reconstituted with saline in a straightforward 50/50 ratio, making it highly convenient for clinicians.

2. The Injectable Form allows for soft tissue management around implants, restorations, and augmentation of keratinized tissue.

-Specifically gingival biotype issues and gingival recession.

-Correction of interdental papilla loss (“black triangles”).

-And Enhancements such as lip augmentation and repair of orthodontic-induced gingival invaginations.

3. The Mixable Form Is Designed For:

-Activation of bone grafting materials for ridge augmentation.

-Treatment of bone defects at tooth or implant sites.

-Management of challenging conditions like osteonecrosis and cleft-palate surgery.

Exceptional Healing Outcomes in Clinical studies demonstrate OraFyl’s significant advantages:

-Accelerated Tissue Integration and Healing: Its molecular scaffold supports the recruitment and colonization of essential cells such as fibroblasts, osteoblasts, and macrophages, facilitating rapid healing.

-Predictable Clinical Outcomes: OraFyl reliably achieves desired soft and hard tissue volumes and shapes, crucial for effective long-term management and patient satisfaction.

-Reduced Soft Tissue and Bone Resorption: Clinical data shows OraFyl significantly reduces tissue shrinkage and bone resorption compared to traditional methods, highlighting its superior performance in alveolar ridge preservation.

Immunological Safety and Compatibility

A remarkable aspect of OraFyl’s usability is its immunological purity, ensuring biocompatibility and minimizing immune reactions. The absence of exogenous growth factors further contributes to a safe healing environment guided by the body’s natural regenerative capabilities.

Final Thoughts

OraFyl’s record-level usability not only simplifies clinical procedures but also enhances patient comfort and outcomes. Its versatility, combined with ease of application and exceptional healing properties, positions OraFyl as the next game-changing advancement in regenerative dentistry.

New Executive Leadership Appointments

https://s3.amazonaws.com/sec.irpass.cc/2739/0001493152-26-030199.htm